[8-K] Abeona Therapeutics Inc. Reports Material Event

Rhea-AI Filing Summary

Abeona Therapeutics, Inc. filed a Current Report on Form 8-K stating that on August 14, 2025 it issued a press release reporting its financial results for the quarter ended June 30, 2025. The press release is filed as Exhibit 99.1 to the report and a Cover Page Interactive Data File is included as Exhibit 104. The 8-K specifies that the press release and related information are incorporated as exhibits but are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference in other filings except by specific reference. The report is signed by CFO Joseph Vazzano.

Insights

Financial Analyst

TL;DR: Routine corporate disclosure; the 8-K attaches a press release with Q2 results but contains no financial figures itself.

The filing notifies investors that a press release with Abeona's quarter ended June 30, 2025 results was issued and is attached as Exhibit 99.1. Because the 8-K text contains no financial data, any assessment of performance or material impact must be based on the exhibit content. The filing also lists an XBRL cover page as Exhibit 104, indicating the company provided interactive data for the disclosure.

Corporate Governance Expert

TL;DR: Standard 8-K legal boilerplate limits Section 18 liability while documenting officer-level sign-off.

The report explicitly states the press release is "not deemed 'filed'" under Section 18 of the Exchange Act and is not incorporated by reference except by specific reference, preserving statutory protections. The filing is executed by Chief Financial Officer Joseph Vazzano, reflecting appropriate officer attestation for the disclosure.

false 0000318306 0000318306 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 14, 2025

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-15771		83-0221517
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

6555 Carnegie Ave, 4th Floor

Cleveland, OH 44103

(Address of principal executive offices) (Zip Code)

(646) 813-4701

(Registrant’s telephone number, including area code)

N /A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ABEO		The Nasdaq Capital Market

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, Abeona Therapeutics Inc. issued a press release regarding its financial results for the quarter ended June 30, 2025. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Abeona Therapeutics Inc. (Registrant)
	By:	/s/ Joseph Vazzano
	Name:	Joseph Vazzano
	Title:	Chief Financial Officer
Date: August 14, 2025

FAQ

What did Abeona Therapeutics (ABEO) file on August 14, 2025?

Answer: Abeona filed a Form 8-K reporting it issued a press release with financial results for the quarter ended June 30, 2025, filed as Exhibit 99.1.

Does the 8-K include the actual financial results for Q2 2025?

Answer: No. The 8-K states a press release with results was issued and attached as an exhibit, but the filing text does not include financial figures.

What exhibits were attached to the 8-K for Abeona (ABEO)?

Answer: The filing lists Exhibit 99.1 (press release dated August 14, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Is the press release considered "filed" for Section 18 liability purposes?

Answer: The 8-K states the press release and related information are not deemed 'filed' for purposes of Section 18 of the Exchange Act and are not incorporated by reference except by specific reference.

Who signed the Form 8-K for Abeona Therapeutics?

Answer: The report is signed by Joseph Vazzano, Chief Financial Officer, dated August 14, 2025.